Takeda's Q1 FY 2026 Earnings Call held on July 30, 2026, highlighted three material pipeline developments: zasocitinib has now demonstrated statistical superiority over deucravacitinib (Sotyktu) across all primary and key secondary endpoints in a head-to-head Phase III psoriasis trial, while a Phase III design change for mezagitamab and and expanding pivotal plans for TAK-928 in non-small cell lung cancer (NSCLC) added further pipeline signals. An August PDUFA date for rusfertide and upcoming approvals for oveporexton remain the company's nearest commercial catalysts.

Takeda Pharmaceutical Company Limited (NYSE: TAK) reported Q1 fiscal year 2026 revenue of JPY 1.22 trillion (approximately USD 8.3 billion), up 10.2% at actual exchange rates but down 0.5% at constant exchange rates. Full-year guidance was unchanged.

Key Strategic Signals

  • Zasocitinib — head-to-head psoriasis superiority: In a Phase III trial against deucravacitinib, zasocitinib — a highly selective oral TYK2 inhibitor — achieved complete skin clearance (PASI 100) in more than 35% of patients at week 16, with R&D President Andrew Plump describing this as "the best 16-week efficacy in psoriasis that we have seen from a pill." Plump said deucravacitinib's performance in the trial was consistent with its prior Phase III results, framing the outcome as a clean comparison rather than an anomaly. Full data are expected at a medical meeting in the fall; US launch remains on track for H1 2027. Phase II readouts for zasocitinib in Crohn's disease and ulcerative colitis are expected by the end of fiscal year 2026, with Plump noting both trials are progressing well.
  • TAK-928 — pivotal program scope expands: TAK-928, a PD-1/IL-2 alpha-biased bispecific fusion protein developed in collaboration with China-based Innovent Biologics, showed a 42% two-year overall survival rate in IO-refractory second-line non-squamous non-small cell lung cancer (NSCLC) at ASCO, against what Plump characterized as an approximately 20% historical benchmark in that population. Takeda plans to initiate a pivotal Phase III in this refractory setting later in fiscal year 2026. Separately, Innovent presented Phase I/II first-line NSCLC data at ASCO showing response rates of approximately 80% in combination with chemotherapy; Plump said a first-line Phase III is also being prepared for initiation this fiscal year, though he cautioned the data are still maturing.
  • Mezagitamab — Phase III design adapted on durability signal: Based on long-term extension data from a Phase Ib/II study showing sustained clinical activity up to two years following only six months of dosing, Takeda modified the Phase III trial design for mezagitamab, an anti-CD38 monoclonal antibody. The original schedule of six months on, six months off has been replaced with a single six-month treatment course followed by follow-up to primary endpoints at one and two years. Plump said the company believes this reflects the underlying pharmacology and disease biology. Phase III studies are ongoing in third-line immune thrombocytopenia (ITP) and IgA nephropathy (IgAN), with a Phase II program recently initiated in antibody-mediated rejection. CEO Julie Kim said peak sales guidance of USD 1 billion to USD 3 billion across ITP and IgAN will be revisited at the Capital Markets Day in December 2026.
  • Orexin franchise — label and lifecycle developments: Oveporexton (Orzeyful), the first-in-class orexin agonist for narcolepsy type 1 (NT1), received its first approval in China during the quarter, with US and Japan decisions expected in Q2. Plump presented Phase III data from the First Light (study 3001) and Radiant Light (study 3002) trials at the SLEEP 2026 meeting, highlighting a shift in REM latency into the normative range across all treatment groups — an outcome he described as "unprecedented." A Phase III study (3003) has been initiated to support EU filing, including data on direct switches from polypharmacy to oveporexton and a higher dose option. Separately, TAK-360, a second orexin agonist, has Phase II studies underway in idiopathic hypersomnia and narcolepsy type 2 using an adaptive design testing both once-daily and twice-daily dosing, with data expected this calendar year; a Phase II in NT1 has also recently started. Plump said the NT1 study reflects early-stage learning about orexin biology rather than any doubt about oveporexton's profile.

Analyst Pressure Points

  • Mezagitamab peak sales range: TD Cowen's Michael Nedelcovych asked whether recent competitive or clinical developments had shifted management's confidence toward either end of the USD 1 billion to USD 3 billion peak sales range. Kim declined to update the estimate ahead of December's Capital Markets Day, while Plump pointed to the durability finding as the most meaningful recent clinical development for the program.
  • TAK-928 first-line data maturity: Bernstein's Miki Sogi pressed Plump on whether the first-line NSCLC data presented at ASCO included the dose expansion cohort with a comparator arm against pembrolizumab plus chemotherapy. Plump acknowledged the data are still maturing and said Takeda has no specific plans to share when the expansion cohort data will be available, but committed to presenting them "in a rapid fashion" once mature.

Forward-Looking Catalysts

  • Rusfertide US launch, H2 2026: Rusfertide, a first-in-class hepcidin mimetic for polycythemia vera, holds FDA priority review with an August PDUFA date. Following Protagonist Therapeutics' opt-out from US co-commercialization in April — at a cost of USD 200 million — Takeda now holds exclusive global rights. An EU filing is targeted later in fiscal year 2026.
  • Zasocitinib IBD Phase II readouts, end of fiscal year 2026: Data from Phase II studies in both Crohn's disease and ulcerative colitis are expected by fiscal year-end. A positive signal in either indication would expand zasocitinib's profile beyond psoriasis ahead of the US launch.
  • Elritercept Phase III initiation in myelodysplastic syndrome and myelofibrosis: Two Phase III trials in first- and second-line myelodysplastic syndrome (MDS) have started, with a pivotal trial in myelofibrosis expected to begin shortly. Elritercept is an activin receptor ligand trap; these initiations represent the first Phase III exposure for the asset and will define its regulatory timeline.

Access the AllSci platform to explore the science behind the news.

Spot something wrong? Report an issue with this article